William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 18,750 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company's stock, valued at $25,742,347.58. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

William Lewis also recently made the following trade(s):

• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Performance

INSM stock traded down $0.54 during midday trading on Monday, hitting $79.38. The stock had a trading volume of 1,338,984 shares, compared to its average volume of 2,179,440. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a 50-day simple moving average of $77.43 and a 200 day simple moving average of $73.79. The firm has a market capitalization of $14.37 billion, a price-to-earnings ratio of -14.20 and a beta of 1.28.

Remove Ads

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Several large investors have recently modified their holdings of the stock. Elequin Capital LP bought a new stake in Insmed during the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC grew its stake in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in Insmed in the 4th quarter valued at $47,000. Finally, Smartleaf Asset Management LLC increased its position in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 411 shares during the period.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Morgan Stanley increased their price objective on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Truist Financial lifted their price target on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Stifel Nicolaus cut their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.